Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

The COVID-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this pandemic rest on the development of effective interventions. Single and combination monoclonal antibody (mAb) therapeutics have received emergency use authorization(1–3), wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:bioRxiv
Main Authors: Wang, Pengfei, Nair, Manoj S., Liu, Lihong, Iketani, Sho, Luo, Yang, Guo, Yicheng, Wang, Maple, Yu, Jian, Zhang, Baoshan, Kwong, Peter D., Graham, Barney S., Mascola, John R., Chang, Jennifer Y., Yin, Michael T., Sobieszczyk, Magdalena, Kyratsous, Christos A., Shapiro, Lawrence, Sheng, Zizhang, Huang, Yaoxing, Ho, David D.
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7852271/
https://ncbi.nlm.nih.gov/pubmed/33532778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.01.25.428137
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados